Independent
Tenure on this board
6.5 yrs
Meeting calendar
EHC · Annual meeting · Thursday, May 7, 2026
Encompass Health Corp
10 nominees · 3 ballot items.
Election of 10 directors; Ratification of PricewaterhouseCoopers LLP as independent auditor; Advisory approval of named executive officer compensation (say-on-pay).
Market cap
$10.9B
1Y TSR
-7.4%
Board grade
B-
Record date
Mar 9, 2026
Filing
DEF 14A
Meeting concluded · May 7, 2026
Follow how the vote landed and what changed on Encompass Health Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORElect 10 directors to the board to serve until the 2027 annual meeting.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the 2026 audit period.
- 3
Advisory Vote on Executive Compensation (Say-on-Pay
ManagementBoard: FORNon-binding advisory vote to approve the compensation of the named executive officers as disclosed in the proxy statement.
More detail
This advisory 'say-on-pay' proposal asks stockholders to approve, on a non-binding basis, the overall compensation of Encompass Health’s named executive officers as presented in the proxy materials, including the Compensation Discussion and Analysis and related tables. Management seeks this approval to confirm alignment between its executive pay program and shareholder interests, relying on a mix of annual and long-term incentives tied to Adjusted EBITDA, quality/strategic objectives, normalized EPS, ROIC, and relative TSR modifiers. The board and the Compensation and Human Capital Committee recommend a vote FOR, citing robust governance features: capped awards, multi-metric incentive designs, clawback provisions, stock ownership guidelines, limited perquisites, and independent compensation consulting. The board points to historical strong shareholder support (97.6% approval in 2025) and the Committee’s view that the program appropriately balances incentive and risk mitigation as justifications for seeking renewed endorsement. Because the vote is advisory, it does not bind the Company, but the board commits to consider stockholder feedback and to potentially adjust practices if significant opposition emerges; the board also indicates it will hold the advisory vote annually.
Director elections
Nominees on the ballot10
Independent
Tenure on this board
2.6 yrs
Independent
Tenure on this board
0.5 yrs
Also a director at
Docusign Inc (DOCU)
Independent
Tenure on this board
13.5 yrs
Also a director at
Ionis Pharmaceuticals Inc (IONS)
Independent
Tenure on this board
13.5 yrs
Independent
Tenure on this board
4.3 yrs
Independent
Tenure on this board
4.8 yrs
Also a director at
Embecta Corp (EMBC)
Independent
Tenure on this board
8.6 yrs
Also a director at
Baxter International Inc (BAX)
Independent
Tenure on this board
6.5 yrs
Not independent
Tenure on this board
9.5 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | 5.6% | 5,521,152 | $534M |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5.0% | 4,959,545 | $480M |
| 3 | PRICE T ROWE ASSOCIATES INC /MD/ | 4.5% | 4,496,608 | $435M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 4.5% | 4,466,237 | $432M |
| 5 | WELLINGTON MANAGEMENT GROUP LLP | 3.4% | 3,395,320 | $328M |
| 6 | BlackRock, Inc. | 3.4% | 3,385,832 | $328M |
| 7 | T. Rowe Price Investment Management, Inc. | 3.3% | 3,228,026 | $312M |
| 8 | STATE STREET CORP | 3.2% | 3,144,974 | $304M |
| 9 | Invesco Ltd. | 2.9% | 2,869,114 | $278M |
| 10 | ALLIANCEBERNSTEIN L.P. | 2.6% | 2,621,245 | $278M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Encompass Health Corp’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Apogee Therapeutics IncAPGE
Special meeting·Aug 11, 2026·$10.1B
Jazz Pharmaceuticals PLCJAZZ
Annual meeting·Jul 23, 2026·$15.0B
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.5B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$4.1B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.5B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.5B
Reference
Frequently asked questions
- When is the Encompass Health Corp 2026 annual meeting?
- Encompass Health Corp (EHC) holds its 2026 annual shareholder meeting on Thursday, May 7, 2026.
- What is the record date for the Encompass Health Corp 2026 meeting?
- The record date for the Encompass Health Corp 2026 meeting is Monday, March 9, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Encompass Health Corp's 2026 meeting?
- The board is presenting 10 director nominees at the Encompass Health Corp 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Encompass Health Corp 2026 meeting?
- Shareholders will vote on 3 proposals at the Encompass Health Corp 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.